SINTX Receives Issuance of U.S. Patent for Silicon Nitride-Functionalized Zirconia-Toughened Alumina Ceramic Biomaterial
SINTX Technologies (NASDAQ: SINT) has been granted U.S. Patent No. 12,239,761 by the USPTO, strengthening its intellectual property portfolio in silicon nitride innovation. The patent covers novel methods of adhering silicon nitride to various biomaterial substrates, enhancing biocompatibility and infection resistance in medical implants.
As the only FDA-registered producer of implantable silicon nitride, SINTX's technology portfolio includes monolithic ceramic implants, particulate-based coatings, microspheres, and composite materials. The company's innovations focus on improving osseointegration and reducing bacterial colonization in orthopedic, craniomaxillofacial, dental, and spinal implants.
The company's intellectual property portfolio now comprises 17 issued U.S. patents and 84 pending applications worldwide.
SINTX Technologies (NASDAQ: SINT) ha ricevuto il Brevetto Statunitense n. 12,239,761 dall'USPTO, rafforzando il suo portafoglio di proprietà intellettuale nell'innovazione del nitruro di silicio. Il brevetto copre metodi innovativi per l'adesione del nitruro di silicio a vari substrati biomateriali, migliorando la biocompatibilità e la resistenza alle infezioni negli impianti medici.
Essendo l'unico produttore registrato presso la FDA di nitruro di silicio impiantabile, il portafoglio tecnologico di SINTX include impianti ceramici monolitici, rivestimenti a base di particelle, microsfere e materiali compositi. Le innovazioni dell'azienda si concentrano sul miglioramento dell'osseointegrazione e sulla riduzione della colonizzazione batterica negli impianti ortopedici, cranio-maxillo-facciali, dentali e spinali.
Il portafoglio di proprietà intellettuale dell'azienda comprende ora 17 brevetti statunitensi concessi e 84 domande pendenti in tutto il mondo.
SINTX Technologies (NASDAQ: SINT) ha recibido la Patente de EE.UU. n. 12,239,761 por parte de la USPTO, fortaleciendo su cartera de propiedad intelectual en innovación de nitruro de silicio. La patente cubre métodos novedosos para adherir nitruro de silicio a varios sustratos biomateriales, mejorando la biocompatibilidad y la resistencia a infecciones en implantes médicos.
Como el único productor registrado por la FDA de nitruro de silicio implantable, el portafolio tecnológico de SINTX incluye implantes cerámicos monolíticos, recubrimientos a base de partículas, microesferas y materiales compuestos. Las innovaciones de la compañía se centran en mejorar la oseointegración y reducir la colonización bacteriana en implantes ortopédicos, cráneo-maxilofaciales, dentales y espinales.
La cartera de propiedad intelectual de la compañía ahora comprende 17 patentes estadounidenses emitidas y 84 solicitudes pendientes en todo el mundo.
SINTX Technologies (NASDAQ: SINT)는 USPTO로부터 미국 특허 번호 12,239,761을 획득하여 실리콘 나이트라이드 혁신에 대한 지식 재산 포트폴리오를 강화했습니다. 이 특허는 다양한 생체 재료 기판에 실리콘 나이트라이드를 부착하는 새로운 방법을 다루며, 의료 임플란트의 생체 적합성과 감염 저항성을 향상시킵니다.
임플란트 가능한 실리콘 나이트라이드의 유일한 FDA 등록 제조업체인 SINTX의 기술 포트폴리오에는 단일 세라믹 임플란트, 입자 기반 코팅, 마이크로스피어 및 복합 재료가 포함됩니다. 회사의 혁신은 정형외과, 두개악안면, 치과 및 척추 임플란트에서 골유착을 개선하고 박테리아 집락화를 줄이는 데 중점을 두고 있습니다.
회사의 지식 재산 포트폴리오는 현재 17개의 미국 특허와 전 세계적으로 84개의 대기 중인 신청서를 포함하고 있습니다.
SINTX Technologies (NASDAQ: SINT) a obtenu le Brevet américain n° 12,239,761 de l'USPTO, renforçant ainsi son portefeuille de propriété intellectuelle dans l'innovation du nitrure de silicium. Le brevet couvre des méthodes novatrices pour adhérer le nitrure de silicium à divers substrats biomatériaux, améliorant la biocompatibilité et la résistance aux infections dans les implants médicaux.
En tant que seul producteur de nitrure de silicium implantable enregistré auprès de la FDA, le portefeuille technologique de SINTX comprend des implants céramiques monolithiques, des revêtements à base de particules, des microsphères et des matériaux composites. Les innovations de l'entreprise se concentrent sur l'amélioration de l'ostéo-intégration et la réduction de la colonisation bactérienne dans les implants orthopédiques, cranio-maxillo-faciaux, dentaires et spinaux.
Le portefeuille de propriété intellectuelle de l'entreprise comprend désormais 17 brevets américains délivrés et 84 demandes en attente dans le monde entier.
SINTX Technologies (NASDAQ: SINT) hat vom USPTO das US-Patent Nr. 12,239,761 erhalten, wodurch das geistige Eigentum im Bereich der Siliziumnitrid-Innovation gestärkt wird. Das Patent umfasst neuartige Methoden zur Haftung von Siliziumnitrid an verschiedenen Biomaterialsubstraten, was die Biokompatibilität und Infektionsresistenz in medizinischen Implantaten verbessert.
Als einziger von der FDA registrierter Hersteller von implantierbarem Siliziumnitrid umfasst das Technologieportfolio von SINTX monolithische Keramikimplantate, partikelbasierte Beschichtungen, Mikrosphären und Verbundmaterialien. Die Innovationen des Unternehmens konzentrieren sich auf die Verbesserung der Osseointegration und die Reduzierung der bakteriellen Besiedelung in orthopädischen, kranio-maxillofazialen, zahnmedizinischen und spinalen Implantaten.
Das geistige Eigentum des Unternehmens umfasst nun 17 erteilte US-Patente und 84 ausstehende Anträge weltweit.
- Secured new U.S. patent strengthening intellectual property position
- Maintains exclusive status as only FDA-registered implantable silicon nitride producer
- Holds substantial IP portfolio with 17 U.S. patents and 84 pending applications
- None.
Insights
This patent issuance marks a pivotal development for SINTX Technologies, substantially strengthening their competitive moat in the advanced ceramics space. The patent's coverage of silicon nitride adhesion methods to various biomaterial substrates is particularly significant for three reasons:
First, as the only FDA-registered producer of implantable silicon nitride, this patent further solidifies SINTX's market exclusivity. The technology's application across multiple medical device categories - from orthopedic to dental implants - creates multiple revenue opportunities through either direct commercialization or licensing agreements.
Second, the patent's timing aligns with growing market demand for antimicrobial medical devices, estimated to reach
Third, with 17 issued U.S. patents and 84 pending applications globally, SINTX is building a formidable intellectual property fortress. This extensive portfolio not only protects their innovations but also creates significant barriers to entry for competitors, potentially leading to valuable licensing opportunities or strategic partnerships with larger medical device manufacturers.
The patent's broad coverage across various biomaterial substrates suggests scalability across different medical applications, potentially reducing development costs while expanding market opportunities. However, it's important to note that patent protection alone doesn't guarantee commercial success - SINTX will need to effectively commercialize these innovations to realize their full value potential.
Salt Lake City, Utah, Feb. 19, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”) an advanced ceramics company specializing in the development and commercialization of materials, components, and technologies for medical and technical applications, today announced the issuance of U.S. Patent No. 12,239,761 by the United States Patent and Trademark Office (USPTO).
This newly issued patent strengthens SINTX’s intellectual property portfolio, further solidifying its position as a global leader in silicon nitride innovation. The patent covers novel advancements in silicon nitride material processing and applications, particularly in the biomedical sector, where the company continues to make significant strides in next-generation implant technology.
“This patent represents another key milestone in SINTX’s ongoing commitment to pioneering advanced silicon nitride solutions,” said Eric K. Olson, President and CEO of SINTX. “With its antiviral, antibacterial, and biomechanical advantages, silicon nitride continues to demonstrate its potential in medical implants, regenerative medicine, and advanced coating technologies. This latest patent reinforces our leadership in the field and strengthens our ability to develop high-performance biomedical applications.”
The patent, developed by the Company covers innovative methods of adhering silicon nitride to a wide array of biomaterial substrates to improve biocompatibility and resistance to infection, expanding its potential applications to orthopedic, craniomaxillofacial, dental and spinal implants. This scientific breakthrough aligns with SINTX’s broader mission to leverage its proprietary technology to improve patient outcomes and surgical success rates.
SINTX is the only FDA-registered producer of implantable silicon nitride, with a robust portfolio that includes monolithic ceramic implants, particulate-based coatings, microspheres and composite materials. These innovations are aimed at enhancing osseointegration and reducing bacterial colonization, key factors in improving implant longevity and patient safety.
With this issuance, SINTX continues to expand its intellectual property portfolio, which now includes 17 issued U.S. patents and 84 pending applications worldwide.
For more information about SINTX Technologies and its silicon nitride platform, visit www.sintx.com.
About SINTX Technologies, Inc.
SINTX Technologies is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008. Over the past several years, SINTX has utilized strategic acquisitions and alliances to enter into new markets. The Company has manufacturing and R&D facilities in Utah and Maryland.
For more information on SINTX Technologies or its materials platform, visit www.sintx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”) that are subject to a number of risks and uncertainties. Forward-looking statements can be identified by words such as: "anticipate," "believe," "project," "estimate," "expect," "strategy,” "future," "likely," "may," "should," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make that the company continues to make significant strides in next-generation implant technology and the potential to pursue growth opportunities and explore strategic opportunities.
Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, technical feasibility and product development. A discussion of other risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements can be found in SINTX’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the SEC on March 27, 2024, and in SINTX’s other filings with the SEC. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report, except as required by law.
Business and Media Inquiries for SINTX:
SINTX Technologies
801.839.3502
IR@sintx.com
FAQ
What is the significance of SINTX's new U.S. Patent No. 12,239,761?
How many patents does SINTX Technologies (SINT) currently hold?
What are the main applications of SINTX's silicon nitride technology?
Is SINTX (SINT) the only FDA-registered producer of implantable silicon nitride?
